Literature DB >> 17362241

Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia.

C Pouplard1, P Gueret, M Fouassier, C Ternisien, M Trossaert, S Régina, Y Gruel.   

Abstract

BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a severe disease that is often difficult to diagnose. A clinical scoring system, the '4Ts' score, has been proposed to estimate its probability before laboratory testing, and a particle gel immunoassay (H/PF4 PaGIA) has also been developed for rapid detection of HIT antibodies. AIM: To evaluate the performance of both methods when HIT is suspected clinically.
METHODS: Two hundred thirteen consecutive patients were included in four centers. The probability of HIT was evaluated using the 4Ts score blind to antibody test results. HIT was confirmed only when the serotonin release assay (SRA) was positive.
RESULTS: The risk of HIT was evaluated by the 4Ts score as low (LowR), intermediate (IR) or high (HR) in 34.7%, 60.6% and 4.7% of patients, respectively. The negative predictive value (NPV) of the 4Ts score was 100%, as the SRA was negative in all LowR patients. PaGIA was negative in 176 patients without HIT (99.4%, NPV) and the negative likelihood ratio (LR-) was 0.05. PaGIA was positive in 37 patients, including 21 with HIT (positive predictive value = 56.8%), with a positive LR of 11.4. A negative PaGIA result decreased the probability of HIT in IR patients from 10.9% before assay to 0.6%, whereas a positive result did not substantially increase the likelihood for HIT.
CONCLUSION: The use of the 4Ts score with PaGIA appears to be a reliable strategy to rule out HIT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17362241     DOI: 10.1111/j.1538-7836.2007.02524.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  34 in total

1.  Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity.

Authors:  Thomas Gremmel; Karin Frühwirth; Christoph W Kopp; Alexandra Kaider; Sabine Steiner; Tamam Bakchoul; Ulrich J H Sachs; Renate Koppensteiner; Simon Panzer
Journal:  Clin Res Cardiol       Date:  2012-01-11       Impact factor: 5.460

Review 2.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Heparin-induced thrombocytopenia.

Authors:  Grace M Lee; Gowthami M Arepally
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

4.  Venous thromboembolic disease.

Authors:  Michael B Streiff; Paula L Bockenstedt; Spero R Cataland; Carolyn Chesney; Charles Eby; John Fanikos; Patrick F Fogarty; Shuwei Gao; Julio Garcia-Aguilar; Samuel Z Goldhaber; Hani Hassoun; Paul Hendrie; Bjorn Holmstrom; Kimberly A Jones; Nicole Kuderer; Jason T Lee; Michael M Millenson; Anne T Neff; Thomas L Ortel; Judy L Smith; Gary C Yee; Anaadriana Zakarija
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

5.  Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients.

Authors:  Vanessa Nellen; Irmela Sulzer; Gabriela Barizzi; Bernhard Lämmle; Lorenzo Alberio
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

6.  Platelet factor 4/heparin-particle gel immunoassay (PaGIA) is a weak method for heparin-induced thrombocytopenia (HIT) evaluation of post cardio-pulmonary bypass surgery patients.

Authors:  Chezi Ganzel; Jacob Rowe; David Raveh
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

7.  Clinical challenge: heparin-induced thrombocytopenia type II (HIT II) or pseudo-HIT in a patient with antiphospholipid syndrome.

Authors:  Jovan Perunicic; Nebojsa M Antonijevic; Predrag Miljic; Valentina Djordjevic; Danijela Mikovic; Mirjana Kovac; Milan Djokic; Igor Mrdovic; Aleksandra Nikolic; Zorana Vasiljevic
Journal:  J Thromb Thrombolysis       Date:  2007-09-09       Impact factor: 2.300

Review 8.  Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

Review 9.  Diagnosis and management of heparin-induced thrombocytopenia.

Authors:  Grace M Lee; Gowthami M Arepally
Journal:  Hematol Oncol Clin North Am       Date:  2013-04-13       Impact factor: 3.722

10.  Novel diagnostic assays for heparin-induced thrombocytopenia.

Authors:  Adam Cuker; Ann H Rux; Jillian L Hinds; May Dela Cruz; Serge V Yarovoi; Isola A M Brown; Wei Yang; Barbara A Konkle; Gowthami M Arepally; Stephen P Watson; Douglas B Cines; Bruce S Sachais
Journal:  Blood       Date:  2013-02-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.